Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • BioCryst scraps eye candidate to focus on rare diseases

BioCryst scraps eye candidate to focus on rare diseases

  • May 6, 2026

The company announced it has concluded development of the plasma kallikrein inhibitor, which was being studied to treat diabetic macular edema.

Leave A Comment

Fields (*) Mark are Required